• CD28 targeting
  • How it works
Radio LAC - Nicolas Fischer, CEO of Light Chain Bioscience

Radio LAC - Nicolas Fischer, CEO of Light Chain Bioscience


"PARLONS ECONOMIE" - Is the future of medicine taking shape in Geneva?

GENEVA, SWITZERLAND/ PARLONS ECONOMIE - RADIO LAC/ JANUARY 28, 2021 /

Discussion about the activities of Light Chain Bioscience | Novimmune SA with Nicolas Fischer, CEO, during his visit to RADIOLAC !

 

See full [PODCAST] FRENCH:

radio lac nicolas fischer ceo of light chain bioscience

Studio RADIO LAC
Rue des Bains 35, 1205 Genève
1205 Genève

022 909 69 69

New publication in Cancer Immunology Research

NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control

Read more

LinkedIn